RZLT Archived Articles
Rezolute: Unlocking Value in Rare Hyperinsulinism with Ersodetug's Phase 3 Momentum (NASDAQ: RZLT)
Published on June 18, 2025
Rezolute, Inc. (RZLT): Pioneering Transformative Therapies for Rare Diseases
Published on March 15, 2025
Rezolute, Inc. (NASDAQ: RZLT): Pioneering Transformative Therapies for Rare Diseases
Published on November 30, 2024
Rezolute, Inc. (RZLT): Transforming Metabolic Diseases with Promising Pipeline
Published on September 24, 2024